CYT003-QbG10: Completed Phase IIa enrollment

Cytos completed enrollment of 60 patients in a double-blind, placebo-controlled, German Phase IIa trial evaluating 7 injections of 900 µg subcutaneous CYT003-QbG10 given over 10 weeks. ...